尼莫拉唑

尼莫拉唑
臨床資料
AHFS/Drugs.com	國際藥品名稱
ATC碼	P01AB06 (WHO) QP51AA06;
識別資訊
	IUPAC命名法 4-[2-(5-nitro-1H-imidazol-1-yl)ethyl]morpholine; ;
CAS號	6506-37-2
PubChem CID	23009;
ChemSpider	21533;
UNII	469ULX0H4G;
KEGG	D07352 ;
CompTox Dashboard（英語：CompTox Chemicals Dashboard） (EPA)	DTXSID1057795 ;
ECHA InfoCard	100.026.723
化學資訊
化學式	C9H14N4O3
摩爾質量	226.24 g·mol−1
3D模型（JSmol（英語：JSmol））	交互式圖像;
	SMILES C1COCCN1CCN2C=NC=C2[N+](=O)[O-];
	InChI InChI=1S/C9H14N4O3/c14-13(15)9-7-10-8-12(9)2-1-11-3-5-16-6-4-11/h7-8H,1-6H2; Key:MDJFHRLTPRPZLY-UHFFFAOYSA-N;

尼莫拉唑（INN：nimorazole，開發代號：K-1900），分子式C₉H₁₄N₄O₃，是一種5-硝基咪唑抗寄生蟲藥^[1]，也用作頭頸癌藥物^[2]^[3]。

參考文獻

^ Roy RB, Laird SM, Heasman L. Treatment of trichomoniasis in the female. A comparison of metronidazole and nimorazole. The British Journal of Venereal Diseases. August 1975, 51 (4): 281–4. PMC 1046566 . PMID 1098732. doi:10.1136/sti.51.4.281.
^ Henk JM, Bishop K, Shepherd SF. Treatment of head and neck cancer with CHART and nimorazole: phase II study. Radiotherapy and Oncology. January 2003, 66 (1): 65–70. PMID 12559522. doi:10.1016/S0167-8140(02)00284-0 .
^ Clinical trial number NCT01507467 for "IAEA-HypoX. Accelerated Radiotherapy With or Without Nimorazole in Squamous Cell Carcinoma of the Head and Neck" at ClinicalTrials.gov